Ileana Farrada, D.O. Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 16401 Nw 2nd Ave Ste 203, North Miami Beach, FL 33169 Phone: 305-999-0009 |
Cliff Glasser, D.O. Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 16401 Nw 2nd Ave, Suite 203, North Miami Beach, FL 33169 Phone: 305-999-0009 |
Dr. Ali Nayer, M.D. Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 2040 Ne 163rd St, Suite 204, North Miami Beach, FL 33162 Phone: 305-615-1514 Fax: 305-501-4731 |
Robenson Jean Marie, MD Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 16695 Ne 10th Ave, North Miami Beach, FL 33162 Phone: 786-615-3430 |
News Archive
Commenting on the Ministerial announcement today, 4 February 2008, on the Review of Public Administration, Dr Ailbe Beirne, Deputy Chairman of BMA(NI) said: "We are pleased to see the Minister continues to be committed to reform of the NHS here and we will be responding in full to the consultation, once it is in the public domain."
Fewer sudden cardiac arrest survivors had neurologic impairment after a novel regional system of care was implemented, according to research published in Circulation, an American Heart Association journal.
People who have received a donor organ need lifelong immunosuppressant drugs to keep their immune system from attacking the foreign tissue. However, with a suppressed immune system, many infectious agents turn into a threat. Infections such as with human cytomegalovirus and a certain type of human polyomavirus frequently cause complications in transplant recipients.
It is well known just how damaging oil can be to nature. It is also well known just how difficult it can be to clean up after a spill or contamination. Removing an oil spill or contamination from soil is hard and requires very different techniques to removing oil from water.
ZymoGenetics, Inc. today announced positive results from a Phase 2 clinical trial in metastatic melanoma with recombinant Interleukin 21 (IL-21) as a single agent. The trial met the primary endpoint of efficacy, as measured by objective response rate or lack of early disease progression. Overall response rate was 23.1%, in evaluable patients, and median progression-free survival was 4.3 months. The results were presented at the American Society of Clinical Oncology meeting.
› Verified 3 days ago